NCT06608420 Precision Medicine for L/GCMN and Melanoma 1
| NCT ID | NCT06608420 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Fundacion Clinic per a la Recerca Biomédica |
| Condition | Melanoma (Skin Cancer) |
| Study Type | OBSERVATIONAL |
| Enrollment | 6,000 participants |
| Start Date | 2024-03-01 |
| Primary Completion | 2026-03-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 6,000 participants in total. It began in 2024-03-01 with a primary completion date of 2026-03-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The primary objective of this study is to create a highly multidimensional and multicentric database for melanoma that encompasses cohorts of children, adolescent and young adults. This database will be used to perform survival analysis and evaluate sentinel lymph node (SLNB) positivity in CAYA. The secondary objectives to be met are the following: * Adaptation and optimization of algorithms: work on optimizing existing precision medicine algorithms, which are currently being used in adult patient care, for their application within pediatric and young adult populations. * Implementation of transfer learning: given the limitations associated with pediatric and young adult data, the investigators intend to utilize transfer learning techniques. The study will employ a sequential waterfall methodology, whereby machine learning models trained on adult patient data will be fine-tuned using the more limited data from younger cohorts. * Integration of expert medical opinion: to integrate physician's scientific domain knowledge into the decision support system. This will be facilitated through the comprehensive examination of existing literature, as well as the evaluation of variable risk contributions within each patient group. * AI-based prognostic models: to develop artificial intelligence-based models for the quantitative prognosis of melanoma across the three age groups: adults, young adults, and children.
Eligibility Criteria
Inclusion Criteria: \- Melanoma patients of any age with histopathological confirmed melanoma Exclusion Criteria: * Not having a melanoma diagnosis * Not having signed the informed consent * Records prior to the year 2012 (as data might not accurately reflect current practices and treatment outcomes)
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06608420 clinical trial?
This trial is open to participants of all sexes, studying Melanoma (Skin Cancer). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06608420 currently recruiting?
Yes, NCT06608420 is actively recruiting participants. Contact the research team at spuig@clinic.cat for enrollment information.
Where is the NCT06608420 trial being conducted?
This trial is being conducted at Barcelona, Spain.
Who is sponsoring the NCT06608420 clinical trial?
NCT06608420 is sponsored by Fundacion Clinic per a la Recerca Biomédica. The trial plans to enroll 6,000 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.